Mirati receives approval from UK’s MHRA for NSCLC therapy
Krazati has been approved as a monotherapy to treat adult patients with advanced NSCLC with KRASG12C mutation and who have progressive disease after previous therapy with, or intolerance
InterAx Biotech has entered a strategic research collaboration and licensing agreement with Alveus Therapeutics to develop a differentiated small-molecule therapeutic candidate for metabolic disease.
Under the multi-year, multi-programme collaboration, the companies will discover, develop, and commercialise therapies for cancer patients. Prelude’s capabilities in medicinal chemistry, targeted protein degradation and clinical development will
Under the deal, Moderna will utilise Caris’ library of de-identified, multi-modal data solutions generated from whole exome sequencing, whole transcriptome sequencing, and protein analyses, in addition to claims